Donald Drakeman, JD, PhD, is a Venture Partner with Advent Life Sciences and a Fellow in Health Management at the University of Cambridge. He was the founding CEO of the biotechnology company that pioneered the field of ‘checkpoint inhibitors’, leading to multiple new treatments for cancer. He is a Distinguished Research Professor in Constitutional Studies at the University of Notre Dame.

Lisa Drakeman, PhD, is the Chair of Volunteers in Medicine, a large charitable clinic for the medically underserved located in coastal South Carolina. She was the founding CEO of a biotechnology company in Europe and the U.S. which set numerous biotechnology financing records and developed a new FDA-approved treatment for cancer. She is a Certified Sommelier.